학술논문
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Document Type
Article
Author
Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M.-J.; Takahashi, S.; Weiss, J.; Machiels, J.-P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C.-Y.; Thungappa, S.C.; Segura, P.P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P.-S.; Baker, V.; Wildsmith, S.; Yovine, A.; Morsli, N.; He, P.; Evans, B.; Olsson, R.F.; Kurland, J.F.; Seiwert, T.Y.
Source
In: Annals of Oncology . (Annals of Oncology, March 2023, 34(3):262-274)
Subject
Language
English
ISSN
15698041
09237534
09237534